EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use

Myrthe R Naber, Mick J M van Eijs, Jildou S Huitema, Jacco J de Haan, Karijn P M Suijkerbuijk, Marijn C Visschedijk, Fiona D M van Schaik

Inflammatory Bowel Diseases · 2026-11-01 · 32 (11) · 2118-2128

DOI: 10.1093/ibd/izag104 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background and Aims Immune checkpoint–inhibitor (ICI) colitis is a common adverse event that is primarily treated with corticosteroids but may require selective immunosuppressive therapy (SIT). Although endoscopic features have been associated with SIT use, it remains unclear whether these associations differ by ICI type. Methods We conducted a 2-center retrospective cohort study and included patients with histologically confirmed ICI colitis. Endoscopic images were reviewed by gastroenterologists specialized in inflammatory bowel disease (IBD) and scored using the Mayo score and the Immune-Mediated Colitis Endoscopic Score (IMCES). Early SIT use was defined as SIT use within 3 weeks after the start of colitis treatment. Features associated with SIT use were stratified by ICI type, and discriminative performance was evaluated using receiver operating characteristic (ROC) analysis. Results Among 255 included patients, 38% required SIT. Biochemical parameters associated with early SIT use were C-reactive protein (CRP) (odds ratio (OR), 1.41; P = .005), and albumin (OR, 0.92; P = .020). Endoscopic features associated with SIT use included erythema (OR, 4.09; P = .006) and exudate (OR, 3.24; P = .012), which were limited to patients treated with anti-cytotoxic T-lymphocyte-associated antigen 4–based (aCTLA-4–based) therapy. In multivariable analysis, ICI type remained the only variable associated with early SIT use (OR, 12.8; P < .001). The IMCES demonstrated areas under the curves (AUCs) of 0.57 (95% CI, 0.50-0.65) for overall and 0.61 (95% CI, 0.53-0.69) for early SIT use. Conclusions In patients with ICI colitis, escalation to SIT use was primarily associated with ICI type, with limited additional value of biochemical or endoscopic features. The IMCES showed poor predictive performance in this external validation cohort.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →